Menu Search
Equities

Rite Aid Corp

RTA1:DUS

Rite Aid Corp

Actions
  • Price (EUR)5.35
  • Today's Change0.072 / 1.36%
  • Shares traded0.00
  • 1 Year change-66.27%
  • Beta--
Data delayed at least 15 minutes, as of May 19 2022 17:01 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Rite Aid Corporation is a healthcare company that operates retail drugstore chain. The Company is principally engaged in providing its service to customers and communities through various programs. Its business segments include Retail Pharmacy segment and Pharmacy Services segment. Retail Pharmacy segment sells brand and generic prescription drugs and various other pharmacy services, as well as front-end products, including health and beauty aids, personal care products and seasonal merchandise. Its Retail Pharmacy segment operates approximately 2,450 retail pharmacy locations across 17 states. Pharmacy Services segment provides a range of pharmacy benefit services through Elixir. Elixir also offers integrated mail-order and specialty pharmacy services through Elixir Pharmacy. The Pharmacy Services segment provides both transparent and traditional pharmacy benefit management (PBM) options through its Elixir PBM. The Company's clients include employers, insurance companies and unions.

  • Revenue in USD (TTM)24.57bn
  • Net income in USD-538.48m
  • Incorporated1968
  • Employees53.00k
  • Location
    Rite Aid Corp30 Hunter LnCAMP HILL 17011-2400United StatesUSA
  • Phone+1 (717) 761-2633
  • Fax+1 (302) 655-5049
  • Websitehttps://www.riteaid.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.